Home / Health / Genentech's New Drug Sheds 10.7% Body Weight
Genentech's New Drug Sheds 10.7% Body Weight
6 Mar
Summary
- Experimental obesity drug petrelintide achieved significant weight loss.
- Patients lost up to 10.7% of body weight in a 493-patient trial.
- Roche gained development rights via a deal with Zealand Pharma.
An experimental drug named petrelintide, a development from Genentech, a subsidiary of Roche, has demonstrated notable efficacy in a recent mid-stage clinical trial. The study, which included 493 participants, revealed that the drug helped individuals achieve significant weight reduction.
Over a 42-week period, patients treated with petrelintide experienced an average body weight loss of up to 10.7%. This outcome contrasts sharply with the 1.7% weight loss observed in participants who received a placebo during the same timeframe. The development of petrelintide is supported by a collaboration and licensing agreement established last year between Roche and Denmark-based Zealand Pharma, granting the Swiss company shared rights to this amylin-based obesity therapy.
